Why the study?
The feasibility of remote perioperative telemonitoring of patient-generated physiologic health data and patient-reported outcomes had not been evaluated in high-risk complex general and urologic oncology surgery patients.
Is remote perioperative telemonitoring feasible in complex general and urologic oncology surgery patients?
Is remote perioperative telemonitoring feasible in complex general and urologic oncology surgery patients?
Remote perioperative telemonitoring is feasible in complex general and urologic oncology patients, with high initial adherence that declines over 30 days postdischarge.
Supports feasibility of remote telemonitoring in complex oncology surgery patients; leaves open impact on outcomes pending randomized trials.
BACKGROUND: The feasibility of remote perioperative telemonitoring of patient-generated physiologic health data and patient-reported outcomes in a high risk complex general and urologic oncology surgery population is evaluated. METHODS: Complex general surgical/urologic oncology patients wore a pedometer, completed ePROs (electronic patient-reported outcome surveys) and record their vitals (weight, pulse, pulse oximetry, blood pressure, and temperature) via a telehealth app platform. Feasibility (% adherence) was assessed as the primary outcome measure. RESULTS: Twenty-one patients with a median age 58 (32-82) years were included. The readmission rate was 33% and the incidence of ≥Grade 3a morbidity was 24%. Adherence to vital sign and ePRO measurements was 95% before surgery, 91% at discharge, and 82%, 68%, and 64% at postdischarge d2, 7, 14, and 30, respectively. There was significant worsening of mobility, self-care and usual daily activity at postdischarge d2 compared to preoperative baseline (p < 0.05). Median daily preoperative steps taken by patients with <Grade 3a versus ≥Grade 3a postoperative morbidity was 6062 versus 4166 (p < 0.05). Of those interviewed, 87% (13/15) viewed vital sign devices as helpful in recovery. CONCLUSIONS: Telemonitoring is feasible in a general surgical and urologic oncology setting. Future studies will ascertain optimal patient selection, duration, and extent of perioperative monitoring.
No takes yet. Share an insight, caveat, or question.
Melstrom et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: